VR Logo

Aligos Therapeutics Inc. (ALGS) download report


Healthcare | Biotechnology & Pharma Research

Aligos Therapeutics Inc. (ALGS) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.

IPO Date: 16-Oct-2020

CEO & Chairman: Dr. Lawrence M. Blatt MBA, Ph.D.

Pres & Director: Dr. Leonid Beigelman Ph.D.

Listing: NASDAQ: ALGS

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.aligos.com

Key Facts

Market cap: $53.37 Mln

Revenue (TTM): $6.02 Mln

Earnings (TTM): $-136.27 Mln

Cash: $183.22 Mln

Total Debt: $14.38 Mln

Insider's Holding: 16.59%

Liquidity: Low

52 Week range: $1.03 - 17.97

Shares outstanding: 39,602,900

Stock Performance

Time Period Aligos Therapeutics (ALGS) S&P BSE Sensex S&P Small-Cap 600
YTD-88.33-7.86-19.66
1 month5.73-3.75-9.44
3 months-35.28-10.80-13.14
1 Year-92.181.50-17.78
3 Years--10.755.52
5 Years--11.435.61
10 Years--11.849.50
As on 06-Jul-2022
Year Aligos Therapeutics (ALGS) S&P Small-Cap 600 S&P BSE Sensex
2021-57.0725.2721.99